Physician profile
Thomas Balcom
NPI 1316766637
$595.60
in general payments reported to CMS, 2019-2025
14 companies · $572 in 2025
The $572 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $23.50 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160.21 | 2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $90.59 | 2025 | Evenity, Prolia |
| Exact Sciences Corporation | $68.54 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $43.37 | 2025 | |
| Aimmune Therapeutics, INC. | $41.00 | 2025 | Zenpep |
| Pfizer INC. | $36.93 | 2025 | |
| Exeltis, USA INC. | $24.17 | 2025 | Slynd |
| Kyowa Kirin, INC. | $23.84 | 2025 | |
| Lilly USA, LLC | $23.50 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $23.04 | 2025 | Pediarix, Bexsero |
| Xeris Pharmaceuticals, INC. | $20.94 | 2025 | Gvoke Hypopen |
| Acadia Pharmaceuticals INC | $18.22 | 2025 | Daybue |
| Corcept Therapeutics | $17.46 | 2025 | Korlym |
| Organon LLC | $3.79 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Balcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.